<DOC>
	<DOC>NCT01588184</DOC>
	<brief_summary>This single-arm, open-label, multicentre extension study will provide continued Avastin [bevacizumab] therapy to patients with solid tumours who were previously enrolled in a Roche/Genentech sponsored study and who derived benefit from the Avastin therapy. Patients will receive the same dose and regimen as used in the previous parent trial and continue this treatment until disease progression or unacceptable toxicity.</brief_summary>
	<brief_title>An Extension Study to Provide Continued Avastin Therapy to Patients With Solid Tumours Who Were Previously Enrolled in a Roche/Genentech Sponsored Study</brief_title>
	<detailed_description />
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Adult patients, &gt;/=18 years of age Patients with solid tumours Patient is treated with Avastin at the end of a Roche/Genentech sponsored parent trial and continues to have benefit from Avastin treatment Eligible for continuation of Avastin treatment at the end of a parent trial Able to comply with this extension study protocol (MO25757) Evidence of disease progression Evidence of any adverse event potentially attributable to Avastin, for which permanent treatment discontinuation is recommended A treatment interruption with Avastin of more than 42 days since the last administration of Avastin in a parent trial Any other disease that would put the patient at high risk for treatmentrelated complications</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>